The SPORE repository has more than 50,000 specimen aliquots from more than 4,500 consented patients with prostate cancer treated at Northwestern Memorial Hospital and NorthShore University Health System. In addition to frozen tissue on nearly 3,500 patients, the repository has blood (serum, plasma, peripheral blood mononuclear cells, and blood spots) and urine samples. Sample accrual has been expanded to include not only patients undergoing surgery, but also non-surgical patients with advanced disease who are undergoing radiotherapy or chemotherapy, thus spanning the spectrum of disease. Corresponding formalin-fixed paraffin-embedded (FFPE) tissue is available on each prostatectomy case, and biopsies are available in most cases as well. More than 50 tissue microarrays have been generated and are available to interested investigators for research studies. Detailed clinical and pathologic data associated with each specimen is uploaded by data coordinators into the SPORE database sample management systems with appropriate protection of patient confidentiality.
Summarize available information for prostate cancer patients at Northwestern Memorial Hospital.
NU Prostate Cancer Patients Who Underwent Surgery
|
Overall, N = 3,747 |
Patients with ≥ 1 Tissue Specimen, N = 3,092 |
Patients with ≥ 1 Non-Tissue Specimen, N = 3,273 |
---|---|---|---|
Gleason, N (%) |
|
|
|
Grade Group 1 (≤ 6) |
1,337 (36%) |
1,083 (35%) |
1,152 (35%) |
Grade Group 2 (3+4) |
1,365 (36%) |
1,139 (37%) |
1,200 (37%) |
Grade Group 3 (4+3) |
631 (17%) |
528 (17%) |
563 (17%) |
Grade Group 4 (8) |
119 (3.2%) |
106 (3.4%) |
103 (3.1%) |
Grade Group 5 (9 or 10) |
284 (7.6%) |
231 (7.5%) |
247 (7.5%) |
Missing |
11 (0.3%) |
5 (0.2%) |
8 (0.2%) |
PSA Follow-up |
|
|
|
Has PSA Follow-up, N (%)1 |
3,422 (91%) |
2,823 (91%) |
2,991 (91%) |
Time to Last PSA Follow-up (Months), Median (IQR)2 |
83 (44, 137) |
83 (44, 137) |
82 (44, 133) |
Vital Status, N (%) |
|
|
|
Alive |
3,438 (92%) |
2,843 (92%) |
3,016 (92%) |
Dead |
305 (8.1%) |
247 (8.0%) |
253 (7.7%) |
Missing |
4 (0.1%) |
2 (<0.1%) |
4 (0.1%) |
Follow-up |
|
|
|
Time to Last Follow-Up (Months), Median (IQR)23 |
140 (92, 179) |
141 (92, 180) |
136 (92, 174) |
Disease Status, N (%) |
|
|
|
Has PSA Recurrence4 |
1,107 (30%) |
906 (29%) |
969 (30%) |
Has Distant Metastasis5 |
110 (2.9%) |
86 (2.8%) |
86 (2.6%) |
1PSA follow-up defined as PSA lab at least 6 months post-surgery. |
|||
2Time measured in months from date of surgery. |
|||
3Follow-up calculated among alive patients. |
|||
4PSA recurrence defined as PSA lab > 0.01 ng/mL at least 6 weeks post-surgery and confirmatory PSA lab > 0.01 ng/mL 2 weeks later. |
|||
5Has distant metastasis date in REDCap recurrence instrument. |
Available Specimens for NU Prostate Cancer Patients Who Underwent Surgery
|
N = 3,747 |
---|---|
Specimen Type, N (%) |
|
FFPE Block1 |
685 (18%) |
Frozen Tissue |
2,890 (77%) |
PBMC |
2,129 (57%) |
Plasma |
2,809 (75%) |
Prostatic Fluid |
1,521 (41%) |
Seminal Vesical Fluid |
646 (17%) |
Serum |
2,834 (76%) |
Urine |
422 (11%) |
Whole Blood |
1,376 (37%) |
1FFPE blocks may be available on all consented patients through NM Pathology. |
Available Aliquots for NU Prostate Cancer Patients Who Underwent Surgery
|
N = 59,890 |
---|---|
Aliquot Type, N |
|
FFPE Block1 |
11,421 |
Frozen Tissue |
10,989 |
PBMC |
3,945 |
Plasma |
8,780 |
Prostatic Fluid |
1,534 |
Seminal Vesical Fluid |
650 |
Serum |
6,473 |
Urine |
1,650 |
Whole Blood |
2,018 |
1FFPE blocks may be available on all consented patients through NM Pathology. |